People with HIV have altered levels of a specific RNA molecule related to both aging and inflammation. This molecule remains altered even with antiretroviral treatment, indicating that their immune system remains affected despite receiving antiretroviral treatment and controlling the infection. The authors of the study, published in the Journal of Microbiology, Immunology, and Infection, suggest that the origin of this alteration is chronic inflammation caused by the infection, regardless of the treatment received by patients. Having this marker can be helpful in monitoring the evolution of patients and the effectiveness of the drugs they take to restore the normal functioning of their immune system.
24/11/2023 - General information
33 new research projects received funding of up to 500,000 euros or up to one million euros in the sixth edition of the CaixaResearch Health Research call, promoted by the "la Caixa" Foundation. In total, 25.3 million euros in grants. The call supports basic, clinical, or translational research projects with scientific excellence and social impact in cardiovascular diseases, infections, oncology, and neurosciences. It also supports projects developing enabling technologies in these areas. Among the selected projects is one led by Dr. Toni Celià-Terrassa to advance the understanding of metastasis and its coevolution with the immune system. There are also two other projects with the participation of researchers from the Hospital del Mar, Dr. Víctor Pérez, and Dr. Arnau Busquets.
The Lancet Public Health journal has published the results of one of the largest and most up-to-date studies worldwide to evaluate the point prevalence of clinically relevant depressive symptoms.
03/11/2023 - General information
The award was given to a study presented by Dr. Joan Jiménez Balado from the Neurovascular Research Group at the Hospital del Mar Research Institute. The study titled "DNA-Methylation and Stroke Prognosis: an Epigenome-wide Association Study," presented by Dr. Joan Jiménez Balado, received the award for Best Communication at the 29th edition of the Stroke Genetics Workshop organized by the International Stroke Genetics Consortium in Boston, United States, from October 12 to 14.
Més informació "Award for Best Communication at the Stroke Genetics Workshop"
02/11/2023 - General information
On Monday, October 30th, the Anti-Doping Laboratory of Catalonia received a visit from Catalan sports authorities: Mrs. Anna Caula Paretas, Secretary General of Sports and Physical Activity; Mr. Aleix Villatoro Oliver, Director of the Catalan Sports Council (CCE); and Dr. Daniel Brotons Cuixart, Head of the Sports and Health Unit of the CCE. The Laboratory is one of the 30 laboratories accredited worldwide by the World Anti-Doping Agency (WADA) to analyze samples from athletes. The visit showcased its complexity, as it has to meet stringent technical and quality requirements imposed by WADA to maintain accreditation.
Més informació "Visits by Catalan Sports Authorities to the Anti-Doping Laboratory of Catalonia"
11/07/2023 - General information
The Tatiana Foundation Prize for Young Researchers, awarded by the Spanish Society of Neurosciences, aims to identify and support the future leaders of Spanish neuroscience research. Valero, coordinator of the Neural Computation Laboratory at the Hospital del Mar Research Institute, has made extraordinary discoveries that have changed the way neuroscientists think about how local neural microcircuits represent spatial information. The award will be presented next September at the XI World Congress of the International Brain Research Organization (IBRO) to be held in Granada and organized by the Spanish Society of Neurosciences.
29/06/2023 - General information
The project, jointly coordinated by UPF professor Ferran Sanz, has enjoyed the participation of numerous members of the GRIB; the UPF research programme in Medical Bioinformatics and the Hospital del Mar Research Institute, as well as the spinoff Med Bioinformatics Solutions, which emerged from the same programme. eTRANSAFE, the European project to share data on the safety of medicines, has come to fruition. On a single platform, the project has integrated data from more than 10,000 pharmacological studies by reference pharmaceutical companies, from a dozen databases that amass public and private information of clinical and preclinical studies. The project has also developed 'Flame', an open-source machine learning application that allows predicting whether future drugs will have adverse effects.
Més informació "Culmination of the eTRANSAFE project to share data on the safety of medicines"
28/06/2023 - General information
The Mutua Madrileña Foundation has awarded its XX Health Research Grants, worth 2.3 million euros, to 26 clinical studies that will be carried out in hospitals throughout Spain. Six of these research projects will be carried out in Barcelona in the areas of cancer immunotherapy, rare childhood diseases, infant and juvenile mental health and transplantation, and together receive funding of more than 680,000 euros. From the Hospital del Mar Research Institute, Doctor Joaquín Arribas, will carry out a study in the field of immunotherapy in cancer. Specifically, it will perform a prospective analysis of biopsies obtained in a phase 1 clinical trial of dose increase using CAR-t Her 2 biospecific cells in patients with advanced solid tumors positive for P95HER2.
14/06/2023 - General information
The Epidemiology and Public Health Program (EPISAP) of the Hospital del Mar Research Institute held its annual meeting on June 7, where the strategic research lines of the groups were shared and the strengths of the program were analyzed. It is worth mentioning the participation in the program of young talented researchers. A consolidated research trajectory together with emerging lines, such as those derived from the COVID-19 pandemic, were highlighted at the meeting. Funding has been received for European projects in areas such as personalized prevention of suicide and depression, measurement of patient reported outcomes (PROs) and the impact on occupational health and safety associated with digital platforms.
Més informació "Annual Meeting of the Epidemiology and Public Health Program"
01/06/2023 - General information
The genomics service of FIMIM, MARGenomics, has recently incorporated the Applied Biosystems GeneChip 3000 Dx v2, a cutting-edge microarray platform funded by the Carlos III Health Institute (ISCIII) and the European Union's NextGenerationEU program. The GeneChip 3000 Dx v2 system holds the distinction of being the first microarray platform in Europe and the United States with regulatory authorization for diagnostic use, thanks to its IVD-R (In Vitro Diagnosis Regulation) certification. This significant development has enabled us to enhance our microarray services by introducing a platform specifically designed for diagnostic purposes, while continuing to offer our traditional gene expression microarray services for experimental research.
Més informació "MARGenomics launches a new microarray platform with IVD-R certification"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
